Focused On-demand Library for Myeloid-derived growth factor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q969H8

UPID:

MYDGF_HUMAN

Alternative names:

Alternative UPACC:

Q969H8; D6W628; O75256; O75272; Q9BTK7; Q9NP69

Background:

The Myeloid-derived growth factor plays a pivotal role in cardiac protection and repair mechanisms, particularly after myocardial infarction (MI). It is a bone marrow-derived monocyte and paracrine-acting protein that not only promotes cardiac myocyte survival but also stimulates adaptive angiogenesis. Its function involves enhancing endothelial cell proliferation through a MAPK1/3-, STAT3-, and CCND1-mediated signaling pathway and inhibiting cardiac myocyte apoptosis via a PI3K/AKT-dependent signaling pathway.

Therapeutic significance:

Understanding the role of Myeloid-derived growth factor could open doors to potential therapeutic strategies. Its involvement in promoting cardiac myocyte survival and stimulating endothelial cell proliferation for angiogenesis highlights its potential as a target for developing treatments aimed at cardiac repair and protection, especially following myocardial infarction.